N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]cyclohexanecarboxamide | 570411-20-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]cyclohexanecarboxamide
• 英文别名: N-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]cyclohexanecarboxamide
• CAS: 570411-20-0
• 化学式: C₂₃H₃₁N₅O
• 分子量: 393.532
• InChiKey: CBAAMEAMYDYAQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  85.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(4-aminobutyl)-2-ethyl-1H-imidazo[4,5-c]quinolin-4-amine 、 环己甲酰氯 以to provide 1.16 g of N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]cyclohexanecarboxamide as a light brown solid, m.p. 201.7-202.5° C.的产率得到N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]cyclohexanecarboxamide
  参考文献：
  名称：

  Amide substituted imidazoquinolines

  摘要：

  在1位点含有酰胺官能团的咪唑喹啉和四氢咪唑喹啉化合物可用作免疫反应调节剂。本发明的化合物和组合物能够诱导各种细胞因子的生物合成，并可用于治疗包括病毒性疾病和肿瘤性疾病在内的各种疾病。

  公开号：

  US07393859B2

文献信息

• Amide substituted imidazoquinolines
  申请人：3M Innovative Properties Company

  公开号：US06756382B2

  公开（公告）日：2004-06-29

  Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

  Imidazoquinoline和在1-位置含有酰胺功能团的四氢咪唑喹啉化合物可用作免疫应答调节剂。本发明的化合物和组合物可以诱导各种细胞因子的生物合成，并可用于治疗包括病毒性疾病和肿瘤性疾病在内的各种疾病。
• Compositions for stimulation of mammalian innate immune resistance to pathogens
  申请人：The Board of Regents, The University of Texas System

  公开号：US10722573B2

  公开（公告）日：2020-07-28

  Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.

  本发明的实施方案涉及治疗、抑制或减弱已感染或有感染风险的个体的微生物感染的方法，包括向该个体施用有效量的 StIR 组合物的步骤。
• COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS
  申请人：The Board of Regents of The University of Texas System

  公开号：EP2411521A1

  公开（公告）日：2012-02-01
• METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION
  申请人：The Board of Regents of The University of Texas System

  公开号：EP3538218A2

  公开（公告）日：2019-09-18
• Methods of treating gastrointestinal inflammation
  申请人：Raz Eyal

  公开号：US20070004654A1

  公开（公告）日：2007-01-04

  The present invention provides methods of treating gastrointestinal inflammation, methods of treating inflammatory bowel disease, methods of treating Crohn's Disease, and methods of treating ulcerative colitis in an individual. The methods generally involve administering an effective amount of an agent that increases the level of a Type I interferon and/or that activates a Type I interferon signaling pathway in the individual.